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Abstract: Gastro-esophageal reflux (GER) is common in infants and children and has a varied clinical
presentation: from infants with innocent regurgitation to infants and children with severe esophageal
and extra-esophageal complications that define pathological gastro-esophageal reflux disease (GERD).
Although the pathophysiology is similar to that of adults, symptoms of GERD in infants and children
are often distinct from classic ones such as heartburn. The passage of gastric contents into the
esophagus is a normal phenomenon occurring many times a day both in adults and children, but,
in infants, several factors contribute to exacerbate this phenomenon, including a liquid milk-based
diet, recumbent position and both structural and functional immaturity of the gastro-esophageal
junction. This article focuses on the presentation, diagnosis and treatment of GERD that occurs in
infants and children, based on available and current guidelines.
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1. Introduction
Gastro-esophageal reflux (GER) refers to the involuntary passage of gastric contents into the
esophagus. In children, it often represents a physiological phenomenon, especially in infants with
innocent regurgitation. Conversely, GER disease (GERD) occurs when the reflux of gastric contents
causes troublesome symptoms and/or complications. It is one of the most common causes of foregut
symptoms across all pediatric age groups [1,2].
Even though the pathophysiology and symptoms, especially in older children, of pediatric GERD
are similar to those in adults, children may also present with a wide range of distinct gastro-esophageal
and extra-esophageal symptoms and potential complications [3].
The conservative approach of “educate-test-treat” seems to be especially important in infants,
where regurgitation most commonly reflects physiological immaturity of the gastro-esophageal
junction, including a short distance and lack of the acute angle between the esophagus and the
gastric fundus (angle of His), where the food is initially stored after ingestion. This physiological
immaturity is often transient and improves without any medical intervention but raises the possibility
of over-medicalization of GER during infancy and potential adverse consequences of attempted
treatment without expected clinical benefits. There are, however, pediatric patient with potentially
severe or persistent GERD, which warrant further assessment and attention given to the potential
long-term consequences of the disease itself, with consideration to side effects of its treatment as well.
The following article focuses on the presentation, diagnosis and treatment of GERD in the pediatric
population as well as differences with GERD in adults.
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2. Evolution and Natural Course of Regurgitation in the Pediatric Age Group
The passage of gastric content into the esophagus (i.e., GER) is a normal phenomenon occurring
many times a day, in both adults and children. Infants are especially prone to regurgitate and it has
been shown that the number of infants with this phenomenon decreases from about 80% during
the first month of life to less than 10% at the age of one year [4]. A study by Miyazawa et al. on
921 infants showed that over 47% of one-month-old infants have one or more regurgitation or vomiting
episodes per day, however this number falls to just 6.4% by the age of seven months [5]. Several factors
contribute to exacerbate this phenomenon in the youngest infants, including the sole or predominantly
liquid milk-based diet, the recumbent position and the immaturity of the function and structure of the
gastro-esophageal junction [6].
Understanding the natural history and outcomes of GERD in children is very important to identify
patients at risk of GERD-related complications and the persistence of symptoms into the adulthood.
In a longitudinal study, Orenstein et al. studied infants with GERD symptoms and histological changes
in the esophagus in the first year of life and found that in a significant proportion of infants histology
remained abnormal, despite complete resolution of symptoms without pharmacotherapy [7]. In a
retrospective/prospective cohort study of adolescents and young adults who were diagnosed in
childhood with GERD, defined by erosive esophagitis, it was shown that later in life almost 80% of
these patients had at least monthly heartburn and/or acid regurgitation and almost one third was
taking either anti-secretory drugs or proton pump inhibitors [8]. In another study by Waring et al.,
255 adult patients with GERD and 154 “non-refluxers” were given questionnaires asking them to
recall childhood symptoms of GERD. The study showed that adults with GERD were more likely to
have experienced GER symptoms during childhood [9]. These studies suggest that in a significant
percentage of children with GERD, symptoms may persist throughout the adolescence until the
adulthood. However, large longitudinal studies are still needed to prove this relation.
3. Clinical Presentation of GERD in the Pediatric Population
3.1. When to Suspect GERD?
Physiological gastro-esophageal reflux (GER) occurs in 40% to 65% of all otherwise healthy infants
between the ages of one and four months making it a fairly characteristic condition of early postnatal
life. Because of high rate of GER in infancy, it is important to distinguish between what is physiologic
and what is a pathologic reaction or symptom. In physiologic regurgitation (“spitting” or posseting)
the process is mostly passive or effortless and the endpoint of the gastric material that has refluxed
up into the esophagus is commonly the oropharynx. In vomiting, the material is forcefully expelled
from the mouth, however both these symptoms are sometimes difficult to differentiate, hence other
symptoms or complications should be investigated [10].
GERD occurs when reflux of the gastric contents causes symptoms that are troublesome, affect
the quality of life or cause pathologic complications, the details are listed below:
Weight loss or inadequate weight gain
Crying and fussiness during and after feeding
Emesis and/or hematemesis
Irritability
Anemia
Bad breath, gagging or choking at the end of feeding
Sleeping disturbance and frequent night waking
Abdominal pain
Dental erosion
Dystonic neck posturing (Sandifer syndrome)
Dysphagia
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Apnea
Respiratory symptoms (aspiration, recurrent pneumonia, chronic stridor, wheezing)
These symptoms are often non-specific and can either mimic or be caused by other
infancy-related conditions, such as cow’s milk protein allergy, pyloric stenosis, malrotation,
overfeeding, tracheo-esophageal fistula or constipation. Therefore, a thorough medical history and
examination is crucial for appropriate diagnosis and treatment.
Unlike adults and older children, infants and small children are not able to verbalize their
symptoms and a number of non-verbal symptoms and signs have been used as surrogates. Irritability
coupled with back arching in infants is thought to be an equivalent of heartburn in older children.
Other causes of irritability and abnormal movements, including cow’s milk protein allergy, neurologic
disorders, constipation and infection, should be ruled out. In children aged 2–12 years, the main
symptoms include regurgitation, vomiting, abdominal pain and feeding difficulties, but typical GER
symptoms can be reliably assessed in children 8–12 years of age [11]. Nelson et al. have shown how
the GERD symptoms can vary depending on the age of the patient (Table 1) [3].
Table 1. Gastro-esophageal reflux disease (GERD)—Age related symptoms [10–12].
Age of the Patients GERD Symptoms
Children <2 years of age
Regurgitation and vomiting
Irritability with feeds and in postprandial period
Back arching
Crying
Food refusal
Cough
Apnea
Children 3–17 years of age
Regurgitation and vomiting
Heartburn
Nausea
Epigastric pain/stomachache
Cough and wheezing
In their study, parents of 3- to 9-year-old children reported that their children most often
experienced epigastric pain. Older children complained more of heartburn and regurgitation; however,
complaints of abdominal pain were common in both age groups [3].
Certain conditions exist, which predispose to severe, chronic GERD. These include neurologic
impairment, obesity, anatomical anomalies like esophageal atresia, hiatal hernia or achalasia, cystic
fibrosis, lung transplantation, and a family history of GERD, Barrett’s esophagus or esophageal
adenocarcinoma [11].
3.2. GERD and Food Allergy
In children, the prevalence of food allergy is estimated to be approximately 6–8%, with some
studies reporting prevalence even of up to 18% [13,14]. Both, regurgitation and vomiting are
well-recognized clinical manifestations of food allergy, mainly of cow’s milk protein allergy (CMPA),
which represents the most common food allergy in early childhood. Although it is difficult to
discriminate between GERD and allergy driven GER symptoms based only on clinical picture, this is
particularly important with regards to the future treatment.
Although the presentation of CMPA overlaps with GERD, and both conditions may commonly
coexist in both infants and children, studies addressing the relationship between these two entities
showed an overall association ranging between 16% and 55%, far beyond what can be expected
from pure coincidence. Nielsen et al showed that 56% of children with severe GERD were found to
have CMPA on double-blind or open challenge [15]. Subsequently, Yukselen and Celtik studied the
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frequency of food allergy in children below five years of age with poor response of GERD symptoms
to pharmacological treatment and found a prevalence of food allergy of 43% in the study group,
with more than a third of patients (38.4%) showing an allergic reaction only to cow’s milk protein [16].
Previous studies on food allergy (CMPA and immunoglobulin E-dependent allergy) in GERD in
children have shown similar results reporting an association between 43% and 48% [17,18].
As the prevalence of both GERD and food allergy diagnoses have increased over the last decade,
together with an increase in proton-pump inhibitor and H2 receptor antagonist prescriptions, this has
raised questions about the possible effects of altered gastric pH on the development of food allergy.
Based on animal studies, antacid medication impairs the gastric digestion of proteins, with the potential
of forming novel dietary proteins, which in turn could promote specific IgE synthesis and lead to food
allergy [19]. Trikha et al. showed that children exposed to gastric acid suppressants due to GERD were
twice as likely to be diagnosed with food allergy after a year of treatment compared to healthy controls,
as well as to children with GERD on conservative (non-pharmacological) treatment only [20].
Several studies have also shown that at least in a subset of patients, GERD is not only associated
with CMPA, but also can be induced by it. Indeed, Borrelli et al. showed in 17 children with CMPA and
suspected GERD that cow’s milk exposure increases the number of weakly acidic reflux episodes [21].
However, taking into account that food allergy with predominant gastro-intestinal symptoms is mostly
non-IgE related, other pathophysiologic mechanisms underlying the relationship between allergy and
GERD should be taken into consideration and need further investigations.
3.3. GERD and Respiratory Symptoms
Symptoms arising from the respiratory tract are common in the pediatric population. Several studies
have suggested a link between GERD and respiratory symptoms with a number of pathophysiologic
mechanisms proposed to explain this, including aspiration of gastric contents into the respiratory tree,
vagal reflexes induced by the presence of gastric contents in the esophageal lumen, and sensitization of
the central cough reflex [22,23]. Borrelli et al compared the type and physical characteristics of reflux
episodes in 24 children with cough-related GER with that found in children with erosive GERD [24]. No
differences between the two groups were found in terms of total reflux episodes, number of acid, weakly
acidic and weakly alkaline reflux episodes or indeed of the proximal extent of reflux episodes. They did
show, however, that 66% of cough bursts were related to acid reflux episodes, whilst the remaining one
third of episodes were related to either weakly acid or alkaline reflux, suggesting that cough symptoms
can be associated with all types of reflux, although acid reflux appears the main determinant in the
genesis of cough-related GER. Different results were shown in a study of 145 children by Zenzeri et al.
Although the authors showed similar numbers of proximal reflux episodes (i.e., reflux events reaching
one or two most proximal impedance channels) in patients with GERD-related respiratory symptoms
compared to children with GERD presenting with only gastro-intestinal (GI) symptoms [25], significantly
higher numbers of weakly alkaline reflux in the study group (children >1 year of age with reflux-related
respiratory symptoms) rather than acid reflux were seen. This supported the hypothesis that reflux acidity
is not the main cause of respiratory symptoms and therefore the treatment based on acid suppressants is
less effective in this group of patients [25].
In a large retrospective cross-sectional study of 1980 children with GERD and 7920 controls, the
authors showed a significantly higher occurrence of sinusitis, laryngitis, asthma, pneumonia and
bronchiectasis in patients suffering from GERD [26]. In another study, although there appeared to
be a significantly higher prevalence of asthma in children with GERD presenting with respiratory
symptoms compared to subjects presenting with GI symptoms only (35.3% vs. 5.3%, respectively),
the overall prevalence of asthma in patients with and without GERD was similar [27]. Therefore,
although an association between asthma and GERD is advocated, the cause–effect relationship needs
further elucidation.
The range of different diagnostic methodologies used in research studies affects result
interpretation, including the lack of a standardized definition for respiratory disease and/or symptoms,
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or the lack of a clearly temporal relationship between the onset of respiratory and GERD symptoms
and/or signs. Moreover, it is difficult to evaluate whether children with GERD are at increased
risk of respiratory diseases in studies that do not assess the prevalence of the same disorders in a
control group. Another confounding factor is that the evaluation of GERD prevalence in children
with respiratory disorders by using diagnostic methodologies cannot be extrapolated to the general
population, as pediatric gastroenterologists generally investigate children only after the failure of
conventional therapy.
3.4. GERD and Extraintestinal Symptoms
Previous data suggest that younger patients tend to have more extraintestinal symptoms, whereas
adolescent children more often have classical GERD symptoms [26]. Outside the respiratory tract,
children can present with neurological signs of reflux like dystonia, Sandifer syndrome (i.e., torticollis
of the head and neck with dystonic posturing of the upper body), opisthotonus or tic disorder,
mimicking neurological disorders. In a group of 46 children with such symptoms (dystonia, Sandifer
syndrome, opisthotonus, tic disorder), Pilic et al. found pathologic results of multichannel intraluminal
pH-impedance in 50% of patients [28].
Ghaem at al. showed that infants with GERD (n = 76) had a higher prevalence of sleep
disturbances requiring parental interventions and significantly delayed onset of sleeping through the
night compared to non-GERD controls [29]. In some groups of patients with complex underlying
conditions, e.g., neurologically impaired, syndromic, etc., GERD may be suspected in the presence
of atypical or unusual symptoms. In patients with Cornelia de Lange syndrome, where reflux is a
common and severe complication, a strong correlation between GERD and bruxism (i.e., grinding
the teeth and clenching the jaw), nocturnal agitation and hyperactivity was suggested [30]. In older
children with cerebral palsy, one of the sings of GERD is dental erosion due to the increased exposure
to gastric acidic content. Other conditions related to high risk of GERD complications are listed below:
Neurologic impairment
Obesity
History of esophageal atresia (repaired)
Hiatal hernia
Achalasia (post treatment)
Chronic respiratory disorders
Bronchopulmonary dysplasia
Idiopathic interstitial fibrosis
Cystic fibrosis
History of lung transplantation
Prematurity
3.5. GERD and Congenital Gastrointestinal Disorders
Acquired (secondary) GERD can also occur with a number of congenital anomalies, including
congenital diaphragmatic hernia, absence of diaphragmatic crura, omphalocele, gastroschisis,
esophageal atresia and intestinal malrotation, with reported incidences as high as 50–84% [31]. The
exact cause for GERD in some of these congenital conditions remains unknown, but it is likely to
include increased intra-abdominal pressure, disturbances of esophageal motor and gastro-esophageal
junction activity along with impacts from other associated anomalies, and disturbances of small bowel
motor activity. With regards to diaphragmatic hernia, GERD is not only a very common concomitant
disorder, but it also associated with long-term severe complications in adulthood, including Barrett’s
esophagus in over 50% of cases [32,33]. Weakness of the crura and the location of the crural diaphragm
(relative to sphincter location), esophageal dysmotility and shortening of the esophagus are some of
the potential causes of the GERD in these patients.
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The most common congenital esophageal malformation is esophageal atresia (EA), with the
reported incidence ranging from one in 2500 to one in 3500 live births [34,35]. The outcome of the
surgical repair depends mainly on the type of the EA, with up to 50% of those with an associated
tracheo-esophageal fistula suffering from GERD [31]. This tendency seems to increase with time [36,37].
Patients with EA are more likely to develop severe GERD due to multiple reasons: impaired anatomy
with hiatus hernia or abnormal position of the intrathoracic part of esophagus, as well as due to
complications arising from the vagal nerve injury (gastroparesis or delayed gastric emptying and
esophageal motor activity dysfunction affecting esophageal acid clearance) [38].
Further details of the underlying pathophysiologic mechanisms of GERD development go beyond
the scope of this article; however, it is important to remember that, in these conditions, their management
has to be weighed against the potentially long term and often severe consequences of GERD.
4. Current Diagnostics Guidelines
According to current guidelines [11,39,40], no single test is sufficient to make a reliable diagnosis
of GERD, as it is often a result of combined clinical assessment and diagnostic tests. Nonetheless,
due to the multifaceted clinical presentation and the frequent occurrence of episodic regurgitation in
otherwise healthy children, discriminating what is “physiologic” gastro-esophageal reflux (GER) from
what is “pathological” gastro-esophageal reflux disease (GERD) can be challenging, particularly in
infants. However, the accurate distinction between these two entities is the pivotal step in the correct
management of GERD, as it reflects decisions about further investigation and treatment.
Recognized GERD-promoting conditions highlighted by the most recent European and North
American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN and
NASPGHAN) guidelines are listed in the paragraph 3.4 [11]. In these populations, the likelihood of
severe GERD is much higher and can predict a worse outcome of the disorder, defining an “at risk”
group of patients in which further investigation and management is advisable.
4.1. Symptom Questionnaires
Age-specific symptom-assessing questionnaires have been developed to ease the clinical diagnosis
of GERD in both, adults and children [41]. However, to date, no single symptom or cluster of symptoms
has been shown to reliably identify patients with GERD and/or predict the response to treatment. The
lack of correlation between reported symptoms and objectively assessed reflux relies on a number of
factors and is particularly evident in infants. In this setting, GERD tends to present with a plethora of
symptoms, not clearly attributable to reflux and that can mimic other conditions, particularly cow’s
milk protein allergy (CMPA). Furthermore, the frequent occurrence of physiological GER and parental
anxiety might lead to an overestimation of the presence of GERD in this population [42]. Consequently,
clinical assessment in children aged <2 years should focus on excluding other potential worrying
conditions that can present with regurgitation and vomiting, rather than making a clinical diagnosis
of GERD. For this purpose, the current guidelines recognize a cluster of “red flags” symptoms that
require further diagnostic testing, the details are listed below:
Bilious vomiting
Gastrointestinal bleeding
Hematemesis
Hematochezia
Consistently forceful vomiting
Onset of vomiting after 6 months of life
Failure to thrive
Diarrhea
Constipation
Fever
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Lethargy
Hepatosplenomegaly
Bulging fontanelle
Macro/microcephaly
Seizures
Abdominal tenderness or distension
Documented or suspected genetic/metabolic syndrome
On the contrary, older children and adolescents tend to resemble their adult counterparts,
complaining of more classical symptoms of heartburn and acid regurgitation [11], making a clinical
diagnosis of GERD more consistent, in terms of specificity and sensitivity. However, the reported
specificity and sensitivity of symptoms-based questionnaires varies widely and is estimated to be 70%
and 65%, respectively, in adult patients with reflux disease [43]. In patients with extra-esophageal
manifestations, these ratios drop further, making it very unlikely to achieve, using questionnaires, a
clinical-based diagnosis of GERD in adults or children.
4.2. Proton Pump Inhibitors Test
The proton pump inhibitor (PPI) trial is a valuable diagnostic and therapeutic tool for GERD. It
consists of an empirical short period (usually 2–4 weeks) of acid suppression with PPI therapy that
can be prolonged up to 12 weeks in case of clinical improvement. The reduction by at least 50% of
symptom severity after treatment is considered highly suggestive of GERD. Although biased by poor
specificity [44], the PPI trial still represents the first-line therapeutic and diagnostic tool in adults,
in primary care settings. Such an approach can be used in older children and adolescents presenting
with typical GERD symptoms, without alarm signs. However, to date, no solid evidence supports this
trial in younger children and infants; hence, although it is still a matter of huge debate, the authors
discourage the “ex iuvantibus” diagnosis of GERD in these age groups, as it can lead to inappropriate
prescription of PPIs and exposure to potential side effects [45–47]. As more extensively discussed below
(see Section 5.2), the inappropriate use of acid suppressive drugs has been indeed associated with
consistent modifications in the intestinal microbiota by inducing gastric hypochlorhydria, delaying
gastric emptying and increasing gastric mucous viscosity [48]. In adults, chronic acid suppression has
been linked to an increased risk of small intestine bacterial overgrowth (SIBO). Although not reaching
statistical significance, a trend towards an increased risk of SIBO has also been recently observed in
children under long-term PPIs therapy (>6 months) [49]. Apart from SIBO, the chronic use of acid
suppressive agents is a well-known risk factor for gastrointestinal (acute gastroenteritis, Clostidium
difficile infection, candidemia and necrotizing enterocolitis) and extra-intestinal (lower respiratory
tract infections, community acquired pneumonia) infections, particularly in infants.
4.3. Endoscopy and Esophageal Biopsies
Similar to adults, the use of an upper gastro-intestinal endoscopy in children should be reserved
to patients with alarm or refractory symptoms of GERD, to excluding its complications or aimed at
ruling out other conditions mimicking GERD [11]. The avoidance of unnecessary invasive testing
is particularly valid in pediatric populations where the benefits of the procedure must be weighed
against the possible risks of the anesthesia.
In children, the macroscopic appearance of the mucosa does not correlate with the histological
findings of esophagitis. Histological examination is essential in differentiating “true” GERD from other
conditions that can resemble GERD, particularly eosinophilic esophagitis (EoE), where obtaining
multiple orientated biopsy samples from different areas of the esophageal body is mandatory,
according to current guidelines [50]. Notwithstanding, esophageal eosinophilia is found in cow’s milk
protein allergy (CMPA) patients and even in asymptomatic infants (aged <1 year) [51]. Furthermore,
inflammatory infiltration of the esophageal mucosa can be patchy in children and is far more frequently
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seen, as compared to adults [52]. Presently, insufficient data exist to support the use of histology as a
diagnostic tool for GERD in children [11,53].
4.4. Upper Gastrointestinal Contrast Studies
Current guidelines do not recommend routinely performing an upper gastrointestinal contrast study
in the evaluation of children with suspected GERD. In selected patients, barium contrast studies may
have a role to exclude conditions that may resemble GERD, such as achalasia, while, in infants, the barium
meal can be useful for the diagnostic evaluation of malrotation, duodenal web and pyloric stenosis.
In addition, although endoscopy is a valid tool to exclude strictures and may raise suspicion of
achalasia and malrotation, the features of the narrowing are more consistently studied with barium
contrast swallows, which are less invasive. Anatomic and functional studies of the esophagus represent
the gold standard in the diagnosis of these conditions.
Gastro-esophageal scintigraphy by measuring post-prandial reflux and gastric emptying has been
advocated as a diagnostic tool of GERD in pediatric population; however, the lack of standardized normal
values and acquisition techniques does not support its use in the diagnostic workup of GERD patients.
4.5. Reflux Monitoring
Both pH-metry and multiple intraluminal impedance (MII) pH-impedance monitoring are
currently performed in clinical settings to evaluate the presence of reflux and the association between
GER and symptoms. Despite the higher costs, the diagnostic yield of combined pH-impedance
monitoring over pH-metry alone justifies the use of combined pH/MII as the test of choice in detecting
GERD in children [54].
MII pH-impedance monitoring helps to discriminate between acidic (pH < 4), weakly acidic
(4 < pH < 7) and alkaline (pH > 7) GER episodes. In infants, pH-impedance represents a valuable
diagnostic tool, as in this age group, GER episodes are more likely to be weakly acidic and/or alkaline,
even in the absence of anti-secretory treatment. It has been estimated that almost 45% of infants
diagnosed with GERD by MII pH-impedance would have had normal pH-metry [11]. However, in
children no pH impedance parameter appears to correlate with the presence of esophagitis.
In adults, MII pH impedance monitoring enables the detection of non-acidic GER episodes that
might be responsible of refractory symptoms during treatment. Furthermore, it can discriminate
between “true” non-erosive reflux disease (NERD) patients (symptomatic patients with normal
endoscopy and pathological esophageal acid exposure), patients with esophageal hypersensitivity
(symptomatic patients with normal endoscopy, normal esophageal acid exposure and with positive
symptom-reflux association probability) and functional heartburn patients (symptomatic patients with
normal endoscopy, normal esophageal acid exposure and with negative symptom-reflux association
probability). The identification of these clinical entities within the “GERD spectrum” is fundamental,
as it directly influences the choice of treatment. In children, since symptoms are non-specific and
reported by proxy, the symptom-reflux association probability is unreliable and the distinction between
NERD, esophageal hypersensitivity and functional heartburn is not recommended [11]. As in adults,
the role of new pH-impedance parameters, such as baseline impedance, is still matter of discussion.
The measurement of baseline impedance was initially suggested to be useful in predicting the integrity
of the esophageal mucosa and therefore in paving the way of selecting the treatment of infants and
children with suspected esophageal mucosal injury [52,55]. However, this early hypothesis has not
been consistently validated by further studies suggesting that baseline impedance might merely mirror
the phenomena occurring either within the esophageal lumen, such as the acid reflux, or within the
esophageal wall, such as the strength and coordination of esophageal peristalsis [56,57].
4.6. Manometry
Esophageal manometry is not indicated in the diagnostic algorithm of adult or pediatric GERD.
In adults, the main goal of manometry is guiding the correct positioning of pH-impedance probes [55].
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However, manometry might be helpful in excluding esophageal motor disorders (i.e., achalasia and
esophageal spasm) and confirming the clinical suspicion of rumination syndrome, thus discriminating
it from GERD. Consequently, although manometric studies are not routinely recommended in the
management of GERD patients, particularly in children where the insertion of the probe might require
sedation or general anesthesia, it is widely agreed that, when possible, esophageal manometry can be
performed before considering antireflux surgery.
5. Treatment
The therapy of pediatric GERD is based on a combination of conservative measures (i.e., lifestyle
and dietary modifications), pharmacological and, rarely, surgical treatment. As stated above,
the proper state-of the-art approach relies on the correct diagnosis and evaluation of GERD patients.
From a clinical standpoint, it is useful to distinguish between infants/young children and older
children/adolescent GERD management, since the clinical presentation, the choice of the therapy and
the response to treatment significantly differs between the two groups. Below, we will review the
current evidence-based approach in infant GERD and we will then briefly discuss the approach to
older children/adolescents complaining of typical GERD.
5.1. Non-Pharmacological GERD Management in Infants/Young Children
Conservative management is the current first line approach in infantile GERD. It ranges from
feeding and posture modifications to modifying maternal diet in breast-fed infants. As previously
discussed, in this setting, it is crucial to distinguish, “true” GERD and other clinical conditions that can
resemble GERD, with CMPA being the most frequent.
Where there is clinical suspicion of GERD and the patient presents with alarm symptoms (see the
list in paragraph 4.1), he should not be treated, but investigated accordingly (see above). On the
contrary, in the absence of alarm features, patients should be treated conservatively by modifying feeds
and posture. The feeding management strategy has been shown to represent an effective approach in
the otherwise healthy infants with both GER and GERD. It involves modifying feeding frequency and
volume, ensuring the intake of feed per kilogram of weight is appropriate. There is some evidence
for the efficacy of feed thickeners on reducing visible regurgitation [58,59]. However, actual GER
episodes are probably not reduced [58] and concerns have been raised about the putative association
between food thickeners and necrotizing enterocolitis in preterm infants [60,61]. The Food and Drug
Administration (FDA) currently discourages their use in infants born before 37 weeks of gestation.
Patients with GER and GERD may also benefit from changing body position, by keeping them upright
or even in the prone position, especially in the post-prandial period [62–64]. However, due to the
increased incidence of sudden infant death syndrome (SIDS), it is not recommended to advise prone
positioning for GERD during sleep [11], while the left lateral position appear a suitable alternative for
the postural management of infant GERD.
If this first-line management fails to improve symptoms, current pediatric guidelines advise
for a 2–4 weeks trial with cow’s milk protein free diet, by either excluding milk from maternal
diet in breastfed infants or by using hydrolyzed formula in non-breast fed infants. This is the
consequence of the fact that CMPA can resemble GERD and should always be considered as a possible
differential diagnosis, particularly in patients with personal or familial history of atopy. Of note, this
recommendation does not apply to the subset of GER patients, the so-called “happy spitters”.
5.2. Pharmacological GERD Management in Infants/Young Children
The pharmacological treatment of GERD encompasses anti-secretory and prokinetic drugs.
In infants, however, the use of these agents must be reserved for patients with objectively assessed
GERD and increased esophageal acid exposure.
Anti-secretory drugs are the backbone therapy for GERD patients. Both histamine-2 receptor
antagonists (H2RAs), and proton pump inhibitors (PPIs) are approved for clinical use in the pediatric
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population, while, in infants aged <1 year, no proton pump inhibitor formulation is approved,
at present. H2RAs are superior to placebo in healing erosive esophagitis in pediatric populations [65].
Nonetheless, unlike PPIs, H2RAs exhibit tachyphylaxis and tolerance and should not be considered in
the long-term management of GERD.
PPIs have been shown to heal erosive esophagitis more effectively and rapidly than H2RAs and
their chronic use is not associated with increasing tolerance [66]. According to current guidelines,
PPIs should be prescribed at the lowest effective dose, once daily. As discussed elsewhere, abuse
and inappropriate prescription of PPIs is a concerning issue, since it is associated with worrisome
side effects, like increased lower respiratory infections, particularly in infants [67–69]. Furthermore,
long-term PPIs therapy (>2.5 years) has been associated with reduced bone mineralization, induced
moderate hypergastrinemia and the development of enterochromaffin-like (ECL) cell hyperplasia
in up to 50% of children [70]. Lastly, acid suppression itself is a recognized risk factor for
community-acquired pneumonia, gastroenteritis, candidemia and necrotizing enterocolitis in preterm
infants [71–76]. In addition, antacid drugs should not be considered in the management of infant
GERD, as some absorbable components may induce side effects following chronic use (milk-alkali
syndrome, aluminum toxicity, renal failure and hypercalcemia) [77–79]. Hence, the use of chronic acid
suppression should always be weighed against the non-negligible risks of long-term therapy.
The rationale of using prokinetic agents in GERD therapy relies on the evidence that these
agents, by increasing gastric emptying rates, might reduce transient lower esophageal sphincter
relaxation. However, all these therapeutic agents are associated with significant side effects, including
extrapyramidal reactions and heart dysrhythmia; hence their use is currently not recommended [80,81].
Figure 1 summarizes the clinical management of GERD in infants according to current guidelines [11].
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5.3. Older Children/Adolescent GERD
The clinical management of typical GERD symptoms in older children and adolescents does
not differ from that of their adult counterparts and it encompasses lifestyle modifications alongside
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with pharmacological treatment. The advised lifestyle changes for adolescents complaining of GERD
resemble the adult recommendations, ranging from losing weight in overweight/obese adolescents
to change of voluptuary habits, including cessation of smoking and alcohol avoidance. As in
adults, dietary and positioning modifications can be advised in the conservative management of
GERD in older children/adolescents. The use of caffeine, alcohol and acidic/spicy foods should
be discouraged as well, as they are potentially able to trigger GERD symptoms. In addition, eating
small, frequent meals, elevating the head of the bed and avoiding large meals before bedtime are
first-line measures than can be easily applied in GERD management. As discussed before, in older
children/adolescents, GERD tends to present with more typical symptoms, including heartburn
and regurgitation, and the symptom-reporting is more reliable strengthening the likelihood of a
clinical-based diagnosis of GERD. For these reasons, in absence of “red flag” symptoms, a PPI trial for
4–6 weeks can represent a reasonable first-line pharmacological approach in older children/adolescents
complaining of typical GERD symptoms, alongside with lifestyle modifications (Figure 2). Refractory
patients and patients complaining of atypical GERD symptoms, on the other hand, should be referred
for further investigations [11].
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5.4. Indication for Surgical Treatment
The indications for surgical treatment still represent a “grey area” in the management of pediatric
GERD, as most of the literature on this topic is limited to retrospective series. According to current
guidelines, anti-reflux surgery should be reserved for severe relapsing cases and for patients at
high risk of long-term GERD complications [11]. Children, in which GERD is associated with
respiratory co orbidities, including asth a and aspiration pneu onia, should be considered for
surgery, although there is a lack of clinical evidence supporting this [11]. The failure of anti-secretory
therapy does not represent an indication to surgery per se. On the contrary, the lack of response to
phar acological treat ent should warn the clinician and should lead to careful reassess ent of the
patient, questioning GERD as underlying cause of the sy pto s. Other ore infrequent clinical
conditions, such as eosinophilic esophagitis, cycling vomiting syndrome, gastroparesis and rumination
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syndrome should be ruled out by second and third level diagnostic tests (contrast studies, manometry),
before considering further treatment. The careful selection of patients is a key process in children, since
nearly 20% of patients require a redo of the fundoplication and the overall recurrence rate of symptoms
varies between 5% and 15% in different studies [82]. Worse outcomes after Nissen’s fundoplication in
children [79,80], compared to adults, has led to “uncertainty” whether the benefits of fundoplication in
children outweigh the harm of long-term PPI use [71].
6. Conclusions
Despite the high prevalence of the disorder, GERD still represents a challenge, even for the
experienced clinician. In pediatric populations, this is particularly evident due to the multifaceted
clinical presentation and the frequent occurrence of regurgitation in “well infants”. There have been
many efforts thus far to appropriately select patients for investigation and treatment and current
guidelines represent the state-of-the-art approach to patients with suspected GERD. The recommended
approach to adolescents complaining of typical GERD is similar to that of adults, encompassing lifestyle
changes and a four-week trial with PPIs. In children aged less than two years, conservative measures
(i.e., lifestyle and diet modifications) represent the first-line therapeutic strategy. Furthermore, due to
the frequent overlap between GERD and CMPA, it is conceivable to advise a time limited trial of dietary
restriction, especially in the presence of personal or family history of atopy. If non-pharmacological
approaches fail, in the opinion of the authors, patients should be investigated by pH-impedance
monitoring rather than be treated “ex iuvantibus”. The rationale for this strategy relies on the fact
that GER in infants is often only mild acidic and/or alkaline, leading to inappropriate prescription
and PPI abuse in this population. Acid-suppressive therapy is the cornerstone for the treatment of
GERD in both adults and children. Although acid-suppressive drugs show a good profile of safety
and tolerability, there is a real risk of adverse events that must be taken into account, particularly
in long-term treatments. Surgical therapy should be reserved for chronic and relapsing cases and
for patients at high risk of GERD complications. The rates of failure of fundoplication appear to be
higher in children, but this might also reflect the poor selection of the patients and the still vague and
controversial indications for surgical treatment.
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